Elif Ilgaz Aydınlar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elif Ilgaz Aydınlar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aynur Özge
Department of Neurology, Mersin University School of Medicine, Mersin, Turkey
3 shared publications - Ayşenur Şahin
Department of Neurology Acıbadem University Istanbul Türkiye
3 shared publications - Pınar Yalınay Dikmen
Department of Neurology, Acibadem University School of Medicine, Türkiye
3 shared publications - Bahar Taşdelen
Department of Biostatistics and Medical Informatics, Faculty of Medicine, Mersin University, Mersin, Türkiye
2 shared publications - Esme Ekizoğlu
Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey
2 shared publications - Ferda Selçuk
Department of Neurology, Burhan Nalbantoğlu State Hospital, Nicosia, Cyprus
2 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Sex differences in cluster headache, treatment insights, and burden of disease in Türkiye: A multi-center cross-sectional study
Aim: There is a growing recognition of the need for sex-specific approaches in primary headache disorders. Research on sex differences in cluster headache (CH) is quite limited, and examining this data across different populations is crucial for understanding genetic and sociocultural differences. We aimed to investigate sex differences in clinical features, acute treatment responses, and the burden of CH in Türkiye. Methods: This multicenter cross-sectional study was conducted between January and June 2024 and involved patients with CH from tertiary healthcare centers, who met the International Classification of Headache Disorders (ICHD-3) criteria. Patients with cluster-like secondary headache conditions were not included. Sociodemographic data, clinical characteristics, acute treatment responses, and the burden of CH were assessed using a semi-structured questionnaire. Statistical comparisons were done between male and female patients. Results: A total of 318 patients (244 males, 76.7%), with a mean age of 45.0 ± 10.9 years, were included. Previous misdiagnosis rates were significantly higher in females (71.6%) compared to males (50.8%) ( p = 0.002). While the frequency and duration of cluster bouts were similar in both sexes, compared to males, females were more likely to experience headache attacks lasting longer than 2 h (44.3% vs. 60.8%; p < 0.013) and more frequently experience agitation during the attacks (66% vs. 79.7%; p = 0.025). The presence of autonomic symptoms also varied by sex; males reported higher rates of conjunctival injection (52.5% vs. 35.1%; p = 0.009) and facial sweating (37.3% vs. 17.6%; p = 0.002). Males showed a higher therapeutic benefit from subcutaneous sumatriptan (91.7% vs. 66.7%; p = 0.002). Both sexes reported a negative impact of CH on daily life in the previous year, with a mean of 18.3 days in males and 22.5 days in females. Conclusion: Several sex differences were observed in patients with CH: attack duration was longer, agitation during the attacks, and misdiagnosis were more frequent. On the other hand, autonomic features such as conjunctival injection and facial sweating tended to accompany CH attacks more often in males, who responded better to subcutaneous triptan than females. These findings highlight the necessity of investigating the underlying mechanisms of sex-specific differences in future research, as well as the careful consideration of these factors in diagnostic and treatment planning.
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessSex differences in cluster headache, treatment insights, and burden of disease in Türkiye: A multi-center cross-sectional study
Aim: There is a growing recognition of the need for sex-specific approaches in primary headache disorders. Research on sex differences in cluster headache (CH) is quite limited, and examining this data across different populations is crucial for understanding genetic and sociocultural differences. We aimed to investigate sex differences in clinical features, acute treatment responses, and the burden of CH in Türkiye. Methods: This multicenter cross-sectional study was conducted between January and June 2024 and involved patients with CH from tertiary healthcare centers, who met the International Classification of Headache Disorders (ICHD-3) criteria. Patients with cluster-like secondary headache conditions were not included. Sociodemographic data, clinical characteristics, acute treatment responses, and the burden of CH were assessed using a semi-structured questionnaire. Statistical comparisons were done between male and female patients. Results: A total of 318 patients (244 males, 76.7%), with a mean age of 45.0 ± 10.9 years, were included. Previous misdiagnosis rates were significantly higher in females (71.6%) compared to males (50.8%) ( p = 0.002). While the frequency and duration of cluster bouts were similar in both sexes, compared to males, females were more likely to experience headache attacks lasting longer than 2 h (44.3% vs. 60.8%; p < 0.013) and more frequently experience agitation during the attacks (66% vs. 79.7%; p = 0.025). The presence of autonomic symptoms also varied by sex; males reported higher rates of conjunctival injection (52.5% vs. 35.1%; p = 0.009) and facial sweating (37.3% vs. 17.6%; p = 0.002). Males showed a higher therapeutic benefit from subcutaneous sumatriptan (91.7% vs. 66.7%; p = 0.002). Both sexes reported a negative impact of CH on daily life in the previous year, with a mean of 18.3 days in males and 22.5 days in females. Conclusion: Several sex differences were observed in patients with CH: attack duration was longer, agitation during the attacks, and misdiagnosis were more frequent. On the other hand, autonomic features such as conjunctival injection and facial sweating tended to accompany CH attacks more often in males, who responded better to subcutaneous triptan than females. These findings highlight the necessity of investigating the underlying mechanisms of sex-specific differences in future research, as well as the careful consideration of these factors in diagnostic and treatment planning.
- Open Access
- 1 April 2026
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 38 (2) , 83-95
Reliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire
Background: This study aims to assess whether the Turkish version of the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ v2.1) is a reliable and valid tool for evaluating the impact of migraine on daily functioning and overall quality of life. Patients and Methods: This multi-center, descriptive, prospective study included a total of 182 migraine patients between December 2023 and May 2024. All patients were assessed at two visits with a four-week interval. The Turkish MSQ v2.1 was evaluated for comprehensibility, patient-physician reliability, internal consistency, test-retest reliability, and construct validity. Results: Of a total of 182 patients, 19 were male and 163 were female with a mean age of 40.8±12.2 (range, 18 to 73) years. Item comprehensibility was high, with 94 to 97.8% at Visit 1, and from 98.4 to 100% at Visit 2. A strong correlation was observed between self-administered and physician-administered MSQ v2.1 scores at Visit 1 (r = 0.916, p < 0.001). Internal consistency was excellent, with Cronbach’s alpha values of 0.932 at Visit 1 and 0.912 at Visit 2. Test-retest reliability was moderate (r = 0.468, p < 0.001). Construct validity was supported by strong correlations with the Headache Impact Test-6 (r = 0.751 at Visit 1 and r = 0.772 at Visit 2), monthly headache days (r = 0.453 and 0.553), and Numeric Rating Scale scores (r = 0.539 and 0.564), all with p < 0.001. Conclusion: The Turkish MSQ v2.1 is a reliable and valid tool for assessing health-related quality of life (HRQL) in migraine patients. It demonstrates excellent internal consistency, moderate test-retest reliability, and strong correlations with established measures of HRQL, headache severity, migraine frequency, and supporting its use in clinical practice and research.
- 1 April 2026
- Published by Baycinar Tibbi Yayincilik in Ağrı - The Journal of The Turkish Society of Algology
- Vol. 38 (2) , 83-95
Open AccessReliability and validity of Turkish version of Migraine-Specific Quality of Life v2.1 questionnaire
Background: This study aims to assess whether the Turkish version of the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ v2.1) is a reliable and valid tool for evaluating the impact of migraine on daily functioning and overall quality of life. Patients and Methods: This multi-center, descriptive, prospective study included a total of 182 migraine patients between December 2023 and May 2024. All patients were assessed at two visits with a four-week interval. The Turkish MSQ v2.1 was evaluated for comprehensibility, patient-physician reliability, internal consistency, test-retest reliability, and construct validity. Results: Of a total of 182 patients, 19 were male and 163 were female with a mean age of 40.8±12.2 (range, 18 to 73) years. Item comprehensibility was high, with 94 to 97.8% at Visit 1, and from 98.4 to 100% at Visit 2. A strong correlation was observed between self-administered and physician-administered MSQ v2.1 scores at Visit 1 (r = 0.916, p < 0.001). Internal consistency was excellent, with Cronbach’s alpha values of 0.932 at Visit 1 and 0.912 at Visit 2. Test-retest reliability was moderate (r = 0.468, p < 0.001). Construct validity was supported by strong correlations with the Headache Impact Test-6 (r = 0.751 at Visit 1 and r = 0.772 at Visit 2), monthly headache days (r = 0.453 and 0.553), and Numeric Rating Scale scores (r = 0.539 and 0.564), all with p < 0.001. Conclusion: The Turkish MSQ v2.1 is a reliable and valid tool for assessing health-related quality of life (HRQL) in migraine patients. It demonstrates excellent internal consistency, moderate test-retest reliability, and strong correlations with established measures of HRQL, headache severity, migraine frequency, and supporting its use in clinical practice and research.
- 27 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 205
Smoking and cluster headache: clinical, gender, and treatment insights from a cross-sectional cluster analysis
- 27 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (2) , 205
Smoking and cluster headache: clinical, gender, and treatment insights from a cross-sectional cluster analysis
- Open Access
- 27 May 2014
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 15 (1) , 32
The relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine
Background: Depression and anxiety are two phenomena that affect quality of life as well as sexual function. Depression and anxiety levels are reported to be high in migraine sufferers. We aimed to understand whether sexual function in women with migraine was associated to migraine-related disability and frequency of migraine attacks, and whether this relationship was modulated by depressive and anxiety symptoms. Methods: As migraine is more commonly seen in females, a total of 50 women with migraine were included. The diagnosis of migraine with or without aura was confirmed by two specialists in Neurology, according to the second edition of International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) in 2004. Migraine disability assessment scale score, female sexual function index scores, Beck depression inventory score and Beck anxiety inventory scores. Results: Mean MIDAS score was 19.3 ± 12.8, and mean number of migraine attacks per month were 4.3 ± 2.7. Mean Female Sexual Function Index score was 20.9 ± 5.9 and 90% of patients had sexual dysfunction. Sexual dysfunction was not related to MIDAS score or frequency and severity of attacks. No relationship between sexual function and anxiety was found, whereas severity of depressive symptoms was closely related to sexual function. Depressive symptoms affected all dimensions of sexual function, except for pain. Conclusion: Sexual dysfunction seemed to be very common in our patients with migraine, while not related to migraine related disability, frequency of attacks and migraine severity or anxiety. The most important factor that predicted sexual function was depression, which was also independent of disease severity and migraine related disability. While future larger scale studies are needed to clarify the exact relationship, depressive and sexual problems should be properly addressed in all patients with migraine, regardless of disease severity or disability.
- 27 May 2014
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 15 (1) , 32
Open AccessThe relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine
Background: Depression and anxiety are two phenomena that affect quality of life as well as sexual function. Depression and anxiety levels are reported to be high in migraine sufferers. We aimed to understand whether sexual function in women with migraine was associated to migraine-related disability and frequency of migraine attacks, and whether this relationship was modulated by depressive and anxiety symptoms. Methods: As migraine is more commonly seen in females, a total of 50 women with migraine were included. The diagnosis of migraine with or without aura was confirmed by two specialists in Neurology, according to the second edition of International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) in 2004. Migraine disability assessment scale score, female sexual function index scores, Beck depression inventory score and Beck anxiety inventory scores. Results: Mean MIDAS score was 19.3 ± 12.8, and mean number of migraine attacks per month were 4.3 ± 2.7. Mean Female Sexual Function Index score was 20.9 ± 5.9 and 90% of patients had sexual dysfunction. Sexual dysfunction was not related to MIDAS score or frequency and severity of attacks. No relationship between sexual function and anxiety was found, whereas severity of depressive symptoms was closely related to sexual function. Depressive symptoms affected all dimensions of sexual function, except for pain. Conclusion: Sexual dysfunction seemed to be very common in our patients with migraine, while not related to migraine related disability, frequency of attacks and migraine severity or anxiety. The most important factor that predicted sexual function was depression, which was also independent of disease severity and migraine related disability. While future larger scale studies are needed to clarify the exact relationship, depressive and sexual problems should be properly addressed in all patients with migraine, regardless of disease severity or disability.